Search Results

Economic Analysis Compares Endovascular Interventions in Femoropopliteal PAD Treatment

November 3, 2015—An evaluation of the 3-year economic impact of five endovascular strategies for the treatment of femoropopliteal peripheral artery disease (PAD) was presented by Brian DeRubertis, MD, during the second of two Late-Breaking Trials sessions at VIVA 15, the 13th annual Vascular InterVentional Advances meeting.

R3 Vascular’s ELITE-BTK Pivotal Trial of Magnitude Scaffold Commences

April 22, 2025—R3 Vascular Inc. announced that the first patient was enrolled in the company’s ELITE-BTK pivotal trial evaluating its Magnitude next-generation drug-eluting bioresorbable scaffold for below-the-knee (BTK) peripheral artery disease (PAD).

Abbott’s Esprit BTK Scaffold Evaluated in 2-Year Data From LIFE-BTK Trial

November 4, 2024—The 2-year results from the LIFE-BTK randomized controlled trial highlighted the sustained benefits of the Esprit below-the-knee (BTK) drug-eluting resorbable scaffold (Abbott) in treating patients with chronic limb-threatening ischemia (CLTI) and infrapopliteal lesions.

Medtronic Receives Clearance for Lower-Profile HawkOne 6-F Directional Atherectomy System

October 24, 2016—Medtronic plc announced US Food and Drug Administration 510(k) clearance for its HawkOne directional atherectomy system in a new 6-F size to provide a treatment option for patients with peripheral artery disease (PAD) with a single device at a lower profile.

Cagent Begins Serranator OCT Study of Serration Angioplasty Versus POBA in BTK Arteries

April 10, 2025—Cagent Vascular, Inc. announced that the first patient was enrolled in the Serranator OCT study.

Abbott’s Esprit BTK Everolimus-Eluting Resorbable Scaffold System Approved in Canada

October 2, 2025—Abbott announced that Health Canada has authorized the Esprit BTK everolimus-eluting resorbable scaffold system for the treatment of patients with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK).

Concept Medical’s MAGICAL BTK IDE Trial Begins Enrollment

January 16, 2025—Concept Medical Inc., announced the enrollment of the first patient in the pivotal MAGICAL BTK randomized controlled trial, which is being conducted in the United States under an FDA-approved investigational device exemption (IDE).

REALITY Trial Begins for Medtronic's Directional Atherectomy and Drug-Coated Balloon in PAD Treatment

July 27, 2016—Medtronic plc and VIVA Physicians announced that the first patient was enrolled in the REALITY study.

Abbott Begins LIFE-BTK Trial to Evaluate Esprit BTK Drug-Eluting Resorbable Scaffold to Treat CLI

September 3, 2020—Abbott announced the start of the LIFE-BTK clinical trial to evaluate the safety and effectiveness of the company’s new Esprit below-the-knee (BTK) everolimus-eluting resorbable scaffold system.

Five-Year Results From ABSORB BTK Trial Presented

November 6, 2019—The 5-year results of the ABSORB BTK trial—a prospective, nonrandomized, single-center study evaluating a novel bioresorbable, drug-eluting scaffold for the treatment of peripheral artery disease below the knee—were presented by Ramon L. Varcoe, MBBS, MS, PhD, during a late-breaking clinical trial session at VIVA 2019, the Vascular InterVentional Advances meeting held November 4–7 in Las Vegas, Nevada. Prof. Varcoe is Associate Professor of Vascular Surgery at the University of New South Wales in Sydney, Australia.

Abbott’s Esprit BTK Drug-Eluting Resorbable Scaffold Studied in Patients With CLTI

October 25, 2023—Abbott announced late-breaking data from the LIFE-BTK clinical trial evaluating the company’s Esprit below-the-knee (BTK) everolimus-eluting resorbable scaffold system in patients with chronic limb-threatening ischemia (CLTI).